Arteritis
MONDO:0043494An inflammatory process affecting an artery.
Also known as: arteritis, artery inflammation, inflammation of artery, Arteritides, Inflammation, arterial, arterial Inflammation
105 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control OngoingThis study tests whether the drug avacopan can help children aged 6 to 18 with a rare autoimmune disease called ANCA-associated vasculitis, which causes inflammation of blood vessels. About 20 participants will receive avacopan alongside standard treatments like rituximab or cycl…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill aims to tame rare blood vessel disease
Disease control OngoingThis phase 2 trial tests whether adding the oral drug iptacopan to standard therapy (rituximab) helps people with active ANCA vasculitis achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive either iptacopan or a placebo, plus stand…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can we stop this arthritis drug without relapse? new trial aims to find out
Disease control OngoingThis study looks at the best way to stop tocilizumab in people with giant cell arteritis, a type of blood vessel inflammation. About 120 participants will either stop the drug suddenly or taper it slowly over time. The goal is to see which approach leads to fewer relapses and all…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Cheaper drug could rival expensive biologic for rare artery disease
Disease control OngoingThis Phase 3 trial compares two drugs—methotrexate and tocilizumab—for treating giant cell arteritis, a condition that causes inflammation in large arteries. Both drugs are given alongside a tapering course of prednisone. The goal is to see if methotrexate, a cheaper and easier-t…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to tame rare artery disease
Disease control OngoingThis phase 3 trial tests whether upadacitinib (Rinvoq) can help people with Takayasu arteritis, a rare disease that inflames large arteries. About 56 adults who have had a recent relapse despite steroids will receive either upadacitinib or a placebo, along with a steroid taper. T…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
Disease control OngoingThis early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New imaging methods could transform PMR diagnosis
Diagnosis OngoingThis study explores whether ultrasound and PET/CT scans can more accurately diagnose and monitor polymyalgia rheumatica (PMR), a condition causing muscle pain and inflammation. Researchers will follow 98 adults over 50 suspected of having PMR, using imaging at key points during t…
Sponsor: Kresten Krarup Keller • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Heart drug study cancelled before it began
Knowledge-focused TerminatedThis study was designed to see if a cholesterol-lowering drug called a PCSK9 inhibitor could also reduce inflammation in the arteries of people with heart disease. Researchers planned to use a special imaging scan to measure inflammation. The study was withdrawn before enrolling …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC